It’s difficult to imagine how an animal that fits in the palm of one’s hand could be rejiggered to behave like Uncle Harry or Aunt Jo—or, more accurately, Uncle Harry or Aunt Jo with a raging viral infection. But some mice that have been genetically engineered to lack an immune system can do just that because they can accept almost any kind of transplant. This means that they can be made to carry functioning human genes, cells, tissues, and organs, and used to study human diseases in ways that would be ethically unacceptable or technically impossible in humans.

The first humanized mice were created more than two decades ago. Since then, substantial improvements have been made to their transplanted immune systems, improving their reliability as preclinical animal models. There are now four major types of humanized mouse models being used to study everything from diabetes and autoimmunity to cancer and a wide array of infectious diseases.

But no other infectious agent has been more extensively studied in humanized mice than HIV. Though primates are still considered the best model for studying HIV infection, humanized mice have the advantage of being far less costly. As their quality improves, they are becoming integral to HIV research. They have been used, for instance, to test new HIV drugs and the systemic delivery of neutralizing antibodies—highly specific proteins that bind viruses and prevent them from infecting host cells.

In recent years, scientists have designed humanized mice that appear to recapitulate a particularly troublesome aspect of HIV infection: the persistence of HIV in reservoirs of latently infected CD4+ T cells—even after treatment has suppressed the virus to virtually undetectable levels in the blood. Such mice are likely to prove valuable to growing efforts to find a cure for HIV, which have lately focused on reactivating such latent reservoirs so that they can be targeted and destroyed.

Humanized mouse models have also long been sought to aid in the development of an AIDS vaccine. However, limitations in the ability of these models to develop functional T-cell responses against the virus that mimic those in humans—a critical arm of a vaccine-induced response to HIV—has tempered enthusiasm for these small animal models. Moreover, difficulties in infecting humanized mice through their mucosa due to the lack of sufficient human cells in the vaginal, rectal, and gastrointestinal tracts have similarly impeded efforts to use the mice to study HIV transmission and pathogenesis.

But a series of papers published this year suggests researchers have found a way around these barriers—most notably with the creation of the bone marrow-liver-thymus (BLT) humanized mouse. Those mice took a starring role at an all-day symposium at Harvard Medical School in Boston on Nov. 5 devoted to the application of humanized mouse models to AIDS vaccine development. “The immune responses in these models are very similar to what we see in human infection,” said Todd Allen, co-chair of the symposium and principal investigator at The Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT), and Harvard. “But we don’t know yet how well that will play out following vaccination of these mice. The biggest limitation is that this remains a model of a human immune system in a mouse environment.”

A flurry of findings

Allen led a recent study that caused a small stir in AIDS vaccine research circles. He and his colleagues found that BLT mice infected with HIV mounted cellular immune responses that closely mirrored those observed in HIV-infected humans, and...
Moreover that HIV also escaped from those responses in a manner very similar to natural infection. Finally, Allen and his team found that BLT mice carrying a human immune-related gene associated with enhanced control of viral replication suppressed the virus in a way that was virtually identical to how humans who express that same gene control the virus. Allen said his lab is now looking at the potential to induce human HIV-specific immune responses in the humanized mice through vaccination.

Though mice are much smaller than people, they can shed light on how HIV makes its way around the body—as was vividly illustrated by Allen’s Harvard colleague Thorsten Memel. He and his team recently tracked HIV-infected human T cells in the lymph node of a humanized mouse using a high-tech surveillance tool called intravital microscopy. This was the first time scientists have visualized the behavior of such cells in a live animal. The study found that HIV-infected T cells migrate robustly in lymph nodes. A small subset of these infected cells derive from either multiple cell fusions or through multiple adhesions to other CD4+ T cells in the lymph node. These interactions resulted in the formation of long continuous membrane surfaces that increased the length of infected cells some ten-fold. The researchers suggest that all this may facilitate cell-to-cell transmission of the virus and promote widespread HIV dissemination.

In yet another study, scientists injected humanized mouse muscle cells with a modified viral vector optimized for the production of various broadly neutralizing antibodies (bNAbs)—those that target a broad range of HIV’s many genetic variants. They found that the antibodies prevented infection even when the animals were challenged with high doses of HIV. Alex Balazs, a researcher in David Baltimore’s lab at California Institute of Technology, where the experiments were conducted, said it remains to be seen whether the results seen in BLT mice can be replicated in humans. “History has shown us that humans don’t behave like mice,” said Balazs. “We have to be prepared for surprises.”

Humanized mice are contributing to research on novel therapies as well. Rockefeller University scientist Michel Nussenzweig has been testing cocktails of potent bNAbs as a therapy in humanized mice infected with HIV. He and his team have found that giving a single bNAb or even as many as three did not produce durable results; the virus rebounded weeks after the antibody treatment ceased. But when they increased the number of bNAbs used, the virus had still not rebounded in seven of the eight mice after two months. Researchers suspect that the expanding arsenal of more potent antibodies might improve the chances of this strategy working and, if so, might provide an alternative to the daily grind of antiretroviral therapy.

The origins of BLT

The BLT mouse was initially developed by virologist Victor Garcia-Martinez, who is now at the University of North Carolina, in conjunction with a team at the University of Minnesota. Scientists make the mice by surgically transplanting human immune cells into newborn mice. The mice are then irradiated and given transplants of human bone marrow, establishing a source for the human immune system borne by BLT mice. Mice altered this way were found to have a wide range of human immune cells in their peripheral blood; the cells also infiltrated organs in the lungs, GI tract, and liver, just as they would in the human body.

Garcia-Martinez and his team showed that these mice developed human T cells at a furious pace after being injected with the bacterial toxin that causes toxic shock syndrome, or Toxic 1—one sign that their immune systems were similar to that of humans. The researchers also measured the amount of time it took the mice to produce cytokines and found that it corresponded with the time taken to induce human inflammatory responses.

But the transplanted BLT immune system is not identical to a human’s. One challenge, for example, is that antibody-producing cells, known as B lymphocytes, don’t mature properly in the bodies of these mice. Dale Greiner, a University of Massachusetts scientist who has authored two reviews on the impact of humanized mouse models on the study of human disease, said this may be because the lymphoid organs in such mice are disorganized. It is in these organs that the immune responses are amplified and refined, especially those involving the production of neutralizing antibodies—which are these days a central focus of HIV vaccine research.

In humans, he said, all of the components are “where they need to be.” In humanized mice, “it is like walking into a warehouse, where everything is scattered.” Greiner says that the genetic engineering required to remove the immune system in these mice, so that it can be replaced by a human one, might inadvertently disrupt the genes required to “organize” their lymphatic system in an immunologically functional manner.

Still, researchers are optimistic about the future of humanized mice in AIDS vaccine research and appear to believe the BLT model, in particular, can be tweaked and improved to that end. “What I think would really catalyze the field,” said Andrew Tager, a Harvard Medical School scientist who collaborated with Allen on his recent study, “is if there could be funding for a consortium to focus on making this a better model with an eye toward answering more questions about HIV. How can we make the immune responses of the model even better? Do we need to put more human genes in the mice? We have shown we are on track. The time is now.”

FREE SUBSCRIPTIONS:
To obtain a FREE subscription to VAX by e-mail, change your subscription details, or receive multiple print copies of VAX to distribute and/or use in your programs, please go to www.iavireport.org and click on the Subscribe link.
VAX is a bi-monthly bulletin from IAVI Report, the publication on AIDS vaccine research published by the International AIDS Vaccine Initiative (IAVI). It is currently available in English, Spanish, and Portuguese as a downloadable PDF file or an e-mail bulletin. The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. Founded in 1996, IAVI works with partners in 25 countries to research, design and develop AIDS vaccine candidates. In addition, IAVI conducts policy analyses and serves as an advocate for the AIDS vaccine field. For more information, see www.iavi.org.
Printed with soy-based ink on FSC-certified paper. Copyright 2012.
Malaria vaccine candidate less effective in infants

New findings from an ongoing Phase III malaria vaccine trial in Africa suggest that the candidate, RTS,S, reduces the incidence of clinical malaria and severe malaria by a modest 31.3% and 36.6%, respectively, among children 6-12 weeks of age. Published online on Nov. 9 in the New England Journal of Medicine, the results nonetheless find that the efficacy of RTS,S was less than that reported last year for older children enrolled in the same trial (see VAX Nov. 2011 Spotlight Article, A Shot at Fighting Malaria). It also appears to be lower than previously reported in a smaller Phase II trial.

Mary Hamel, a medical epidemiologist at the US Centers for Disease Control and Prevention and a principal investigator at one of the trial’s clinical research centers in Kisumu, Kenya, said researchers should gain some clarity when data from all the sites where the study was conducted are released in the next year or two. “We may find that by pooling the data across the 11 trial sites, differences in vaccine efficacy by malaria transmission intensity were masked,” Hamel says. “Most malaria cases in this analysis were from areas of very high transmission. Efficacy in areas of low or moderate malaria transmission may be higher, consistent with the Phase II trial.”

Developed and manufactured by GlaxoSmithKline (GSK) Biologicals, RTS,S contains a protein found on the surface of the P. falciparum sporozoite—the form of the parasite transmitted from mosquitoes to people—linked to hepatitis B vaccine antigen. It is formulated with AS01, an adjuvant manufactured by GSK.

The RTS,S candidate was co-administered with two licensed vaccines: a pentavalent vaccine against diphtheria, tetanus, pertussis, hepatitis B and Hemophilus influenzae type B, and a polio vaccine. Scientists suggest that the co-administration of the licensed vaccines—including the Hep B antigen, which was effectively delivered twice—may have compromised the immune response to the RTS,S candidate. Hamel adds that infants have immature immune systems that respond less vigorously to vaccination, and that their responses might have been further compromised by antibodies against the sporozoites passed down by their mothers. Lower vaccine efficacy could also be associated with higher-transmission regions, but that will only be known when the site-specific analysis is completed.

The fate of RTS,S remains unclear. The PATH Malaria Vaccine Initiative, which financed most of the research with a $200 million grant from the Bill & Melinda Gates Foundation, hasn’t yet announced any decision. “The efficacy came back lower than we had hoped, but developing a vaccine against a parasite is a very hard thing to do,” said Bill Gates in a statement on PATH’s website. “The trial is continuing, and we look forward to getting more data to help determine whether and how to deploy this vaccine.”

Dybul to lead The Global Fund

Mark Dybul, a medical doctor and immunologist who helped create and then led the President’s Emergency Program for AIDS Relief (PEPFAR) for three years, will be heading up The Global Fund to Fight AIDS, Tuberculosis and Malaria in Geneva.

Dybul’s appointment comes at a particularly rocky time for The Global Fund, a prolific fundraiser that has been grappling with both funding and management problems in recent years (see The Global Fund’s Uncertain Future, IAVI Report, Jan.-Feb. 2012). Dybul replaces Michel Kazatchkine, who left the organization in early 2012, not long after The Global Fund’s board of directors appointed international banker Gabriel Jaramillo to the newly created position of general manager and put him in charge of day-to-day operations.

Dybul was a staff clinician at the US National Institute of Allergy and Infectious Diseases when he joined a task force that led to the creation of PEPFAR in 2003. Since 2009, he has co-directed the Global Health Law Program at the O’Neill Institute for National and Global Health Law at Georgetown University.
Understanding DNA Vaccines

What are the major challenges that AIDS researchers have faced in developing DNA vaccines and how are recent advances helping them overcome these challenges? By Regina McEnery

Many common viral vaccines have been made by either killing a virus of interest or weakening it so that it doesn’t cause disease. When people are immunized with such preparations, they mount an immune response that subsequently protects them from pathogenic strains of the targeted virus. Unfortunately, using a weakened or attenuated version of HIV to stimulate protective immunity remains off limits to developers of AIDS vaccines. HIV mutates very rapidly, changing its genetic makeup dramatically even within one infected individual. Researchers therefore worry that an attenuated HIV could mutate and regain its ability to cause disease. Using a killed version of HIV in a vaccine candidate, meanwhile, is impractical because it is difficult to prove that the virus is completely inactivated. Further, such vaccines have failed to protect monkeys against simian immunodeficiency virus (SIV, the monkey equivalent of HIV).

These concerns have led scientists to look for better and safer methods for creating AIDS vaccine candidates. One such alternative is DNA vaccination, in which genes from a pathogen of interest are injected into people to generate a protective immune response. Essentially, DNA HIV vaccines are composed of harmless pieces of HIV’s own DNA that have been pasted into circular pieces of DNA known as plasmids, which infect bacteria in the wild and have long been used to express genes in laboratories.

After an engineered and purified DNA plasmid is injected into a person—usually with a gene gun into skin and muscle—it is passively taken up by cells. Those cells then use their own protein-making machinery to produce the HIV proteins encoded by the plasmid. This usually results in the activation of the cellular immune response, which targets virally infected cells. But DNA vaccines can also be engineered to elicit antibody responses, which can block the viral invasion of cells and have historically played a central role in vaccine immunization (see Feb. 2004 Primer on Understanding the Immune System, Part 1 and Mar. 2004 Primer on Understanding the Immune System, Part II).

When DNA vaccination was first proposed in the early 1990s, the preclinical data seemed promising. Scientists had found that mice inoculated subcutaneously with genes encoding human growth hormone developed antibodies against that protein. Further, DNA vaccine candidates were even then relatively easy to make and stable at room temperature. Researchers were therefore attracted to this strategy. It meant that such vaccine candidates could be produced relatively rapidly and cheaply in large quantities and would, further, suit the needs of the developing world, where refrigeration capacity is often limited and transportation difficult.

But DNA vaccine candidates also presented some challenges. Most prominently, they triggered relatively weak immune responses because plasmids are not very efficiently taken up by cells. Producing stable forms of engineered plasmid DNA also proved to be harder and more expensive than researchers had expected. These setbacks dampened enthusiasm for DNA vaccines, not just against HIV but other pathogens as well. In fact, no DNA vaccine has yet been licensed to prevent a human disease.

New tools improve responses

In recent years, however, technological advances have revitalized the field of DNA vaccination. One new tool that has contributed to its resurgence is electroporation (EP), a vaccine delivery technology that induces temporary pores in the membranes of muscle or skin cells so that they can more easily take plasmids. Small hand-held EP devices these days often include a needle to inject the vaccine and thin wires that administer short electrical pulses during vaccine delivery.

Initially developed in the 1970s, EP has been refined and tested in a growing number of human studies since the early 1990s. In recent years, EP devices have been tweaked to cause less pain and deliver plasmids more efficiently, and continue to be tested in HIV vaccine trials.

Adjuvants, which stimulate the immune response to vaccines, are also being used to improve DNA-based vaccine candidates. Many licensed vaccines, such as the influenza vaccine, are formulated with chemical adjuvants. But as researchers’ understanding of the immune system and its factors has grown in sophistication, entirely novel adjuvants and methods for their co-delivery are being tried out in clinical trials. Rather than just co-formulate their vaccine candidates with adjuvants, for example, AIDS vaccine developers have designed DNA plasmids to carry genes for proteins that are potent boosters of cellular immune responses. One such protein, Interleukin 12, is naturally produced by dendritic cells—which have long been known to play a central role in vaccine immunization.

Clinical trials are now testing DNA vaccine candidates that are delivered via electroporation along with the gene for IL-12.

Researchers have also tweaked the plasmids used to make DNA vaccines so that human cells can express more of the HIV antigens they encode, and so trigger more robust immune responses. One way they do this is by including in the plasmids promoters—DNA sequences that initiate the reading of genes for protein production—that are more effective at driving gene expression.

Vaccine developers also enhance immune responses by using DNA candidates as a prime, and then boosting the response it provokes with another agent—such as the canarypox viral-vector vaccine candidate that was used in the RV144 trial in Thailand. Any such regimen is referred to as a heterologous prime-boost. The DNA used as the prime focuses the immune response on the vaccine candidate inserts, perhaps with the help of an adjuvant. The subsequent boost enhances the primed response.

Together, new technologies and such traditional immunization strategies have contributed to a resurgence in DNA vaccine development.